BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 23808331)

  • 1. Prions and the potential transmissibility of protein misfolding diseases.
    Kraus A; Groveman BR; Caughey B
    Annu Rev Microbiol; 2013; 67():543-64. PubMed ID: 23808331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Can prion-like propagation occur in neurodegenerative diseases?: in view of transmissible systemic amyloidosis].
    Yoshida K; Higuchi K; Ikeda S
    Brain Nerve; 2012 Jun; 64(6):665-74. PubMed ID: 22647474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Misfolded protein aggregates: mechanisms, structures and potential for disease transmission.
    Moreno-Gonzalez I; Soto C
    Semin Cell Dev Biol; 2011 Jul; 22(5):482-7. PubMed ID: 21571086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal models for prion-like diseases.
    Fernández-Borges N; Eraña H; Venegas V; Elezgarai SR; Harrathi C; Castilla J
    Virus Res; 2015 Sep; 207():5-24. PubMed ID: 25907990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates.
    Soto C; Estrada L; Castilla J
    Trends Biochem Sci; 2006 Mar; 31(3):150-5. PubMed ID: 16473510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The spread of prion-like proteins by lysosomes and tunneling nanotubes: Implications for neurodegenerative diseases.
    Victoria GS; Zurzolo C
    J Cell Biol; 2017 Sep; 216(9):2633-2644. PubMed ID: 28724527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prion and prion-like diseases in animals.
    Aguilar-Calvo P; García C; Espinosa JC; Andreoletti O; Torres JM
    Virus Res; 2015 Sep; 207():82-93. PubMed ID: 25444937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand binding and hydration in protein misfolding: insights from studies of prion and p53 tumor suppressor proteins.
    Silva JL; Vieira TC; Gomes MP; Bom AP; Lima LM; Freitas MS; Ishimaru D; Cordeiro Y; Foguel D
    Acc Chem Res; 2010 Feb; 43(2):271-9. PubMed ID: 19817406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review: membrane-associated misfolded protein propagation in natural transmissible spongiform encephalopathies (TSEs), synthetic prion diseases and Alzheimer's disease.
    Jeffrey M
    Neuropathol Appl Neurobiol; 2013 Apr; 39(3):196-216. PubMed ID: 23171056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic prions and other human neurodegenerative proteinopathies.
    Le NT; Narkiewicz J; Aulić S; Salzano G; Tran HT; Scaini D; Moda F; Giachin G; Legname G
    Virus Res; 2015 Sep; 207():25-37. PubMed ID: 25449570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prion-like disorders and Transmissible Spongiform Encephalopathies: An overview of the mechanistic features that are shared by the various disease-related misfolded proteins.
    Eraña H; Venegas V; Moreno J; Castilla J
    Biochem Biophys Res Commun; 2017 Feb; 483(4):1125-1136. PubMed ID: 27590581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions.
    Caughey B; Baron GS; Chesebro B; Jeffrey M
    Annu Rev Biochem; 2009; 78():177-204. PubMed ID: 19231987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into Mechanisms of Transmission and Pathogenesis from Transgenic Mouse Models of Prion Diseases.
    Moreno JA; Telling GC
    Methods Mol Biol; 2017; 1658():219-252. PubMed ID: 28861793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-molecule approaches to prion protein misfolding.
    Yu H; Dee DR; Woodside MT
    Prion; 2013; 7(2):140-6. PubMed ID: 23357831
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Eraña H; Fernández-Borges N; Elezgarai SR; Harrathi C; Charco JM; Chianini F; Dagleish MP; Ortega G; Millet Ó; Castilla J
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-seeding of prions by aggregated α-synuclein leads to transmissible spongiform encephalopathy.
    Katorcha E; Makarava N; Lee YJ; Lindberg I; Monteiro MJ; Kovacs GG; Baskakov IV
    PLoS Pathog; 2017 Aug; 13(8):e1006563. PubMed ID: 28797122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shape matters: the complex relationship between aggregation and toxicity in protein-misfolding diseases.
    Ries HM; Nussbaum-Krammer C
    Essays Biochem; 2016 Oct; 60(2):181-190. PubMed ID: 27744334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers.
    Ugalde CL; Finkelstein DI; Lawson VA; Hill AF
    J Neurochem; 2016 Oct; 139(2):162-180. PubMed ID: 27529376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prion-Like Protein Aggregates and Type 2 Diabetes.
    Mukherjee A; Soto C
    Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28159831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein misfolding cyclic amplification (PMCA): Current status and future directions.
    Saá P; Cervenakova L
    Virus Res; 2015 Sep; 207():47-61. PubMed ID: 25445341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.